Read More: eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient

At eGenesis, we envision a world in which no one dies while waiting for a transplant.

Engineering hope

0 people require a transplant1

According to the most recent estimates, more than 100,000 people in the U.S. need a transplant due to a failing organ.

0 people added to the kidney waitlist every year2

The waitlist is growing. More than 36,000 patients were added to the kidney transplant waitlist alone in 2020 in the U.S.

0 organ transplants take place each day1

On average, only 106 organ transplants of any kind take place each day in the U.S. The gap between need and availability is always growing.

0 people die every day waiting for a transplant2

The supply of human donor organs and cells cannot serve all patients in need. Every day, 20 people die waiting in the U.S. and this devastating shortage is growing worse.

Transplant shortage statistics tell only part of the story

Homepage Still
In the last 25 years, the gap between the number of candidates on the kidney transplant waitlist and the number of kidney transplants preformed has only widened, as shown by the data from 2020.1

While these numbers are striking, they don’t tell the whole story of the transplant shortage crisis. That story includes the experiences of individuals and families from all backgrounds — their fear, their suffering, and their hope.

At eGenesis, we ask, “Why can’t we end this crisis?” We envision a world in which the supply of transplantable organs and cells does not determine the length or quality of one’s life.

Pushing the bounds of what’s possible in transplantation

Xenotransplantation is recognized as a potential solution to address the transplant shortage. Leading experts, George Church, Ph.D. and Jim Markmann, M.D., Ph.D., discuss the need and opportunities for innovation in the field of xenotransplantation.

George Church

Jim Markmann

Xenotransplantation has many possible frontiers, with kidney and islet cells leading the way.

Developing Human Compatible (HuCo™) organs and cells

Through our transformative research, we are developing HuCo™ organs and cells to meet the increasing need. Our eGenesis Genome Engineering and Production (EGEN™) Platform leverages advances in gene editing technologies to address the historical challenges of xenotransplantation. Our goal is to improve the lives of patients in need of a transplant, their families, and those who care for them.

We are excited to share this powerful and promising story with you.


  1. Health Resources and Services Administration and U.S. Department of Health & Human Services. Organ Procurement and Transplantation Network National Data. Accessed October 6, 2021.
  2. Health Resources and Services Administration. Organ Donation Statistics. Updated October 2021. Accessed October 6, 2021.